Tinengotinib Tablets Accept New Drug Application in China: A Significant Step Forward in Cancer Treatment TransThera Sciences has announced that the new drug application for Tinengotinib tablets has been accepted in China, marking progress in cholangiocarcinoma treatment.

Tinengotinib Tablets Accept New Drug Application in China: A Significant Step Forward in Cancer Treatment #China #Nanjing #oncology #TransThera #tinengotinib

TransThera's Tinengotinib Tablets Gain Priority Review for Cancer Treatment in China TransThera Sciences announces the inclusion of Tinengotinib tablets in the priority review list by China's National Medical Products Administration, potentially enhancing treatment options for cholangiocarcinoma.

TransThera's Tinengotinib Tablets Gain Priority Review for Cancer Treatment in China #China #Nanjing #TransThera #tinengotinib #Cholangiocarcinoma

youtu.be/yjFpFE5wVgo Used to work with #JeanFan Great to see the work that #Transthera is pursuing. She says there are good things on the horizon #shorttakesinoncology @ascocancer.bsky.social #Cancer #cancerresearch

TransThera Unveils Promising Tinengotinib Research Against Cholangiocarcinoma TransThera Sciences has published groundbreaking findings on tinengotinib, an innovative treatment for cholangiocarcinoma, revealing new insights into acquired resistance and potential therapies.

TransThera Unveils Promising Tinengotinib Research Against Cholangiocarcinoma #China #Nanjing #TransThera #tinengotinib #Cholangiocarcinoma

TransThera Unveils Promising Results for Novel BTK Inhibitor in Hematological Malignancies TransThera Sciences has reported encouraging Phase I study results for TT-01488, a novel reversible BTK inhibitor, at the 2024 ASH Annual Meeting.

TransThera Unveils Promising Results for Novel BTK Inhibitor in Hematological Malignancies #China #Nanjing #BTK_Inhibitor #TransThera #TT-01488

TransThera Presents Promising Clinical Data on Tinengotinib for Biliary Tract Carcinoma at 2024 ESMO Asia TransThera Sciences unveiled encouraging findings regarding tinengotinib in combination with atezolizumab for biliary tract carcinoma during the 2024 ESMO Asia Congress.

TransThera Presents Promising Clinical Data on Tinengotinib for Biliary Tract Carcinoma at 2024 ESMO Asia #China #Nanjing #TransThera #tinengotinib #biliary_tract_carcinoma